Alan L. Crane, Member of the Board of Directors of Vaccinex, Inc. Will Not Stand for Re-Election
March 11, 2019 at 05:05 pm EDT
Share
On March 8, 2019, the Nominating and Corporate Governance Committee of the Board of Directors of Vaccinex, Inc. was informed that Alan L. Crane, a member of the Board of Directors, will not stand for re-election at the Company's 2019 Annual Meeting of Stockholders.
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.